Children's Medical Center Corporation

Duke University

Beth Israel Deaconess Medical Center, Inc.

US Government As Represented by the Secretary of the Army

National Institutes of Health, a Component of the US Dept. of Health & Human Services

Harvard College

Leland Stanford Junior University

Novartis Ag

Dana-farber-cancer Institute Inc.

Howard Hughes Medical Institute

The United States of America As Represented by the National Institutes of Health (nih)

Brandeis University

Terralithium LLC

Stephen C Harrison

Bing Chen

Michael Scott Seaman

Barton F Haynes

Dan H Barouch

Joseph P Nkolola

Thomas B Kepler

Philip R Dormitzer

Jerome H Kim

Georgia D Tomaras

Nelson L Michael

Garnett Kelsoe

Yorgo Modis

Hua-Xin Liao

Kai W Wucherpfennig

Ethan Settembre

M Anthony Moody

Xiaojiang Chen

Harry B Greenberg

Gary H Frey

Aaron G Schmidt

Junhua Pan

Dan C Barouch

Joshua Yoder

James Whittle

Joseph P Nkoloa

Nikolaus Grigorieff

Jonathan Abraham

Robert Blanchet

Joseph P Nikolola

Stabilized trimers of a clade A strain and a clade C strain of HIV-1 are provided. Broadly neutralizing antisera against HIV-1, methods of making broadly neutralizing antisera against HIV-1, broadly neutralizing vaccines against HIV-1, as well as methods of treating subjects infected with HIV, preventing HIV infection, and inhibiting HIV-mediated activities are also provided.

Biochemically stabilized HIV-1 Env trimer vaccine

The invention generally provides compositions and methods of treating or preventing an arenavirus infection, using an agent that inhibits binding of an arenavirus glycoprotein 1 (GP1) polypeptide to transferrin receptor 1 (TfR1). The invention also provides methods of designing or identifying therapeutic agents that bind to or target a GP1 receptor-binding site (RBS) to inhibit arenavirus attachment to a cell, and therapeutic agents identified using the methods.

Compositions and methods for treating arenavirus infection

The present invention relates, in general, to human immunodeficiency virus (HIV), and in particular to a vaccine for HIV-1 and to methods of making and using same.

Nucleic acids encoding human immunodeficiency virus type 1 (HIV-1) N-terminal deleted gp120 immunogens and methods of use

The present invention relates, in general, to an HIV-1 vaccine and, in particular, to a B cell lineage-based vaccination protocol.

Methods to identify prime and boost immunogens for use in a B cell lineage-based vaccination protocol

Biochemically stabilized HIV-1 env trimer vaccine

The present invention relates to the use of rotavirus particles for displaying a heterologous protein, alone or in complex with another molecule. The invention further relates to methods that employ these modified rotavirus particles to rapidly determine the structure of the heterologous protein or the complex using cryo-electron microscopy (cryo-EM). The invention also relates to a method of immunizing a patient, wherein said method comprises administering to the patient the modified rotavirus particles of the invention.

Rotavirus particles with chimeric surface proteins

GP120 immunogens and methods inducing neutralizing antibodies to human immunodeficiency virus

Human immunodeficiency virus type 1 (HIV-1) N-terminal deleted GP120 immunogens

The invention features a novel influenza antibody that specifically binds to influenza hemagglutinin and reduces or inhibits hemagglutinin binding to sialic acid. The invention also provides methods, compositions, and kits featuring the novel antibody and its use in preventing or treating influenza infection.

Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza hemagglutinin

Biochemically stabilized HIV-1 ENV trimer vaccine

Isolated, antigenic polypeptides including a prehairpin intermediate conformation of gp41 and vectors encoding such polypeptides are provided. Antibodies that bind to a prehairpin intermediate conformation of gp41 and methods of making antibodies a that bind to prehairpin intermediate conformation of gp41 are also provided. Vaccines against a prehairpin intermediate conformation of gp41, as well as methods of treating subjects infected with HIV, preventing HIV infection, and inhibiting HIV-mediated activities are also provided. Methods of screening compounds that bind to an isolated, prehairpin intermediate conformation of gp41 are further provided.

Fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies

The present invention relates to novel recombinant polypeptide antigens that may comprise subunit vaccines against rotavirus infection. Further, the present invention relates to methods for use of said antigens in the diagnosis, treatment and prevention of rotavirus infection.

Rotavirus antigens

Growing community of inventors

Brighton, MA, United States of America

Stephen C Harrison